Opinion|Videos|July 5, 2024
Expert Insights on Managing Amivantamab Infusion Reactions, Dosing, and Medication
A pharmacy expert explores infusion-related reactions associated with amivantamab, providing guidance on managing and preventing these reactions, while also addressing the role of split-dosing, premedications, and steroids in the treatment paradigm.
Advertisement
Episodes in this series
- Compared to the other EGFR-targeted therapies used in metastatic NSCLC, amivantamab is unique in carrying a risk for infusion-related reactions. What has been your experience with these infusion-related reactions, and what is the typical timing and severity of these reactions?
- What preventative strategies do you recommend to help prevent infusion-related reactions with amivantamab?
- Please discuss package insert recommendations including split-dosing and premedications, and if patients still experience infusion reactions despite these measures. Please discuss the role of preemptively including steroids as part of routine premedication (particularly when given as monotherapy and not already receiving steroids for pemetrexed purposes).
- In your experience and in the context of these toxicities, how do patient-specific factors such as performance status and comorbidities influence the choice of EGFR-targeted therapies?
- Please address considerations related to monotherapy vs. combination therapy (either with chemotherapy or other non-chemotherapy agents)
Advertisement
Related to this article
This update came with no changes to the safety sections of labeling, with no new signals identified with longer follow-up.
The update shortens required observation to 6 to 8 hours from 22 to 24, easing tarlatamab administration in community settings for ES-SCLC.
A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.
Eight-year phase 3 ADAURA trial data show adjuvant osimertinib boosts survival in patients with resected EGFR-mutant NSCLC.
Phase 3 HARMONi-2 interim analysis shows first bispecific PD-1/VEGF antibody outperforming standard immunotherapy in first-line NSCLC.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
4
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
5